within Pharmacolibrary.Drugs.ATC.A;

model A10BJ01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.65,
    Cl             = 0.15166666666666667,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.028300000000000002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is available in both twice-daily injection (Byetta) and long-acting once-weekly (Bydureon) formulations. Exenatide is approved and widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported from healthy subjects and patients with type 2 diabetes after subcutaneous administration of 5 or 10 mcg exenatide. Single- and multiple-dose two-compartment models have been used. Data below reflect findings from key clinical studies and FDA labeling references.</p><h4>References</h4><ol><li><p>Hall, S, et al., &amp; Clements, JN (2018). Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. <i>Clinical pharmacokinetics</i> 57(12) 1529–1538. DOI:<a href=&quot;https://doi.org/10.1007/s40262-018-0668-z&quot;>10.1007/s40262-018-0668-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29915923/&quot;>https://pubmed.ncbi.nlm.nih.gov/29915923</a></p></li><li><p>Cirincione, B, &amp; Mager, DE (2017). Population pharmacokinetics of exenatide. <i>British journal of clinical pharmacology</i> 83(3) 517–526. DOI:<a href=&quot;https://doi.org/10.1111/bcp.13135&quot;>10.1111/bcp.13135</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27650681/&quot;>https://pubmed.ncbi.nlm.nih.gov/27650681</a></p></li><li><p>Vlasakakis, G, et al., &amp; Nunez, DJ (2015). Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers. <i>Advances in therapy</i> 32(7) 650–661. DOI:<a href=&quot;https://doi.org/10.1007/s12325-015-0222-4&quot;>10.1007/s12325-015-0222-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26160357/&quot;>https://pubmed.ncbi.nlm.nih.gov/26160357</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BJ01;
